Category: Cervical cancer

Home / Established Year

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cervical cancer that has worsened..

Pembrolizumab with chemoradiotherapy is approved by the USFDA for FIGO 2014 Stage III-IVA cervical cancer

Pembrolizumab with chemoradiotherapy is approved by the USFDA for FIGO 2014 Stage III-IVA cervical cancer

The Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in combination with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer on January 12, 2024.A study called KEYNOTE-A18 (NCT..

Peter MacCallum Cancer Centre collaboration
, , ,

Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy

March 2023: Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development programme agreement (CDPA) to develop CTH-002 for the treatment of ovarian cancer. The cli..

, , , ,

Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer

Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration for patients with persistent, recurrent, or metastatic cervical cancer ..

, , , ,

Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent or metastatic cervical cancer ..

Gastric acid reflux is actually associated with cervical cancer

People are familiar with the uncomfortable feeling of acid reflux. A recent US study found that gastroesophageal reflux disease (GORD) may increase the risk of laryngeal cancer , tonsil, and some sinus cancers in the elderly ..

Latest treatment option in uterine cancer

According to the latest report from the US Centers for Disease Control and Prevention (CDC), the incidence of almost all cancers has declined in the past two decades, while the incidence of uterine cancer has risen. Doctors began..

Avoid these things to avoid cervical cancer

With the continuous improvement of living standards, the age of people's sexual organ development also continues to decrease. More and more people have sex life at a young age. This will lead to women's problem of incomplete acces..

Cervical cancer myths and misunderstandings

Everyday I will hear that cervical erosion will become cancerous when it is severe. In fact, not all of them will become cancerous. It can only be said that patients with cervical erosion are a dangerous group of cervical cancer. ..

What is the progress of immunotherapy for gynecological tumors?

In recent years, the incidence of gynecological tumors has increased year by year, making the terms cervical cancer and ovarian cancer no longer unfamiliar to us. Cervical cancer is the most common gynecological malignant tumor. ..

Newer
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy